---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-041158"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:25:49.853115+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Praxis Precision Medicines prices $56.50/share offering, expected $215.6M net proceeds

## Summary
- Offering includes 3,318,585 shares at $56.50 and 221,238 pre-funded warrants at $56.4999; underwriters exercised option for 530,973 additional shares.
- Net proceeds of ~$215.6M after discounts and expenses; closing expected April 2, 2024.
- Proceeds to accelerate PRAX-628 development and continue R&D for ulixacaltamide, PRAX-562, and PRAX-222.
- Company believes existing cash plus net proceeds will fund operations into 2027.
- Underwriters: Piper Sandler, Guggenheim Securities, and Truist Securities.

## SEC filing metadata
- accession: 0001104659-24-041158
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000110465924041158/0001104659-24-041158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000110465924041158/tm247764d6_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-041158
- JSON: https://secwatch.observer/filing/0001104659-24-041158.json
- Plain text: https://secwatch.observer/filing/0001104659-24-041158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.